Thu Sep 19 05:44:56 UTC 2024: ## Lexaria Bioscience Outperforms Xeris Biopharma in Investment Analysis: MarketBeat News

**Kelowna, Canada -** Lexaria Bioscience Corp. (NASDAQ:LEXX) has emerged as the stronger investment option compared to Xeris Biopharma (NASDAQ:XERS) according to a recent analysis by MarketBeat News. The two small-cap medical companies were evaluated across a range of factors, including valuation, risk, analyst recommendations, profitability, institutional ownership, dividends, and earnings.

Lexaria Bioscience scored higher in 7 out of 13 categories, including:

* **Lower volatility:** Lexaria’s share price is less volatile than Xeris’, with a beta of 0.98 compared to Xeris’s 2.76.
* **Higher potential upside:** Analysts have set a consensus target price of $11.00 for Lexaria, representing a potential upside of 241.61%. This is significantly higher than Xeris’s target price of $4.67 with a 60.92% potential upside.
* **More affordable:** Lexaria trades at a lower price-to-earnings ratio, making it more affordable than Xeris.
* **Stronger institutional ownership:** Institutional investors hold 13.1% of Lexaria shares compared to 42.8% of Xeris shares, signaling confidence in Lexaria’s future growth.

While Xeris boasts higher revenue, Lexaria has stronger earnings. Lexaria’s DehydraTECH drug delivery technology has garnered significant attention for its potential to enhance the effectiveness and bioavailability of various pharmaceuticals, including cannabinoids, vitamins, and pain medications.

**Investors looking for a more stable and potentially higher-growth investment may find Lexaria Bioscience more attractive than Xeris Biopharma.**

**About Lexaria Bioscience:**

Lexaria Bioscience is a biotechnology company developing and out-licensing its patented DehydraTECH drug delivery technology. This technology enhances the absorption of various molecules, including pharmaceuticals, nutraceuticals, and consumer products.

**About Xeris Biopharma:**

Xeris Biopharma is a biopharmaceutical company developing and commercializing therapies for a range of conditions, including diabetes, hyperkalemia, and Cushing’s syndrome.

**Disclaimer:** This is a summary of the information provided by MarketBeat News and does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions.

Read More